Abstract: Retinopathy of prematurity (ROP) is a vision-threatening disorder that leads to pathological growth of the retinal vasculature due to hypoxia. Here, we investigated the potential effects of Alamandine, a novel heptapeptide in the renin-angiotensin system, on hypoxia-induced retinal neovascularization and its underlying mechanisms. In vivo, the C57BL/6J mice with oxygen-induced retinopathy (OIR) were injected intravitreally with Alamandine (1.0 μM/kg per eye). In vitro, human retinal microvascular endothelial cells (HRMECs) were utilized to investigate the effects of Alamandine (10 μg/ml) on proliferation, apoptosis, migration, and tubular formation under vascular endothelial growth factor (VEGF) stimulation. The LC-MS/MS analysis revealed a significant decrease in Alamandine levels in both the serum and retina of OIR mice when compared to the control group. Next, Alamandine ameliorated hypoxia-induced retinal pathological neovascularization and physiologic revascularization in OIR mice. In vitro, Alamandine effectively mitigated VEGF-induced proliferation, scratch-wound healing, and tube formation of HRMECs primarily by inhibiting the HIF-1α/VEGF pathway. Further, coincubation with D-Pro7 (Mas-related G protein-coupled receptor D (MrgD) antagonist) hindered the beneficial impacts of Alamandine on hypoxia-induced pathological angiogenesis both in vivo and in vitro. Our findings suggested that Alamandine could mitigate retinal neovascularization by targeting the MrgD-mediated HIF-1α/VEGFA pathway, providing a potential therapeutic agent for OIR prevention and treatment.